Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation

Mamun, Abdullah Al; Nsiah, Nana Yaa; Srinivasan, Meenakshi; Chaturvedula, Ayyappa; Basha, Riyaz; Cross, Deanna; Jones, Harlan P.; Nandy, Karabi; Vishwanatha, Jamboor K.

doi:10.18865/ed.29.3.517

Cited by 16 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“……further mentoring workforce strategies could benefit from a personalized framework that emphasizes individualized and tailored approaches … as pharmacogenomics or participant diversity, that are related to disparities. This customized mentored approach is consistent with the emphasis on diversity in the era of precision medicine 36 and, in short, emphasizes delivering the right mentoring to the right investigators and for the right population groups under research.…”

Section: Formal Evaluationmentioning

confidence: 57%

Mentoring Programs by and for a New Generation of Latino Investigators in Behavioral-Social Science HIV Research

2020

View full text Add to dashboard Cite

Latinos represent a critical resource of talent that could be cultivated to expand the HIV research workforce. However, their rapid growth, as the largest and fastest growing ethnic minority group in the US population, has yet to translate into a significant increase in Latino health academic researchers. Historically, strategies to build a diverse research workforce have grouped together individuals from underrepresented minority populations obscuring significance between and within group differences. This limits approaches that are responsive to the diversity of needs and experiences of emerging investigators from underrepresented groups.In this article, we discuss challenges associated with heterogeneity of Latinos and barriers that impede research independence/ career success in the context of a review of Latino-investigator targeted mentorship approaches on the behavioral-social science of HIV infection. Mentorship workforce strategies could benefit from a personalized framework emphasizing individualized and tailored approaches to address the limitations and gaps in knowledge regarding Latino research development. This perspective encourages increased emphasis on organizational and structural processes to aid in overcoming institutional-level barriers that impede research and career development. Recommendations are proposed for features and components of effective mentorship programs that will lead to robust outcomes for strengthening the Latino research workforce in the HIV research field and elsewhere.Ethn Dis. 2020;30(2):305- 312; doi:10.18865/ed.30.2.305.

show abstract

Section: Formal Evaluationmentioning

confidence: 57%

Mentoring Programs by and for a New Generation of Latino Investigators in Behavioral-Social Science HIV Research

2020

View full text Add to dashboard Cite

show abstract

“…Attention to these issues will improve our ability to understand cancer biology in different contexts from the biological behavior of cancer in different groups to the metabolism and toxicity of drugs in different hosts to the efficacy of the therapeutics. Indeed, there is a need to address diversity and equity if we are to fulfill the promise of precision medicine to provide the best care possible to each individual (31)(32)(33).…”

Section: Limitations In Basic Science Widens Disparitiesmentioning

confidence: 99%

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology

El‐Deiry

Giaccone

2021

Front. Oncol.

View full text Add to dashboard Cite

Disparities are common and well-known in the field of clinical oncology and cancer research. In patient care, poor access and a number of other factors disadvantage patients and this can lead to inadequate screening, prevention or treatment of cancer and poor patient outcomes. World-wide, socioeconomic status, health care expenditures and a number of other challenges contribute to disparities in cancer care and patient outcomes. Access to cancer clinical trials remains inadequate for underrepresented minorities as well as non-white racial and ethnic groups. There are also disparities and many challenges in the biomedical research enterprise that can limit innovation and that must be addressed as part of active interventions.

show abstract

“…However, the resulting clinical and genomic data is often siloed within these institutions, leading many to push for mandatory data sharing 9,10 . These efforts, while critical to democratizing genomic research, do not directly improve access to molecular research programs and do not address underlying ethnic, socioeconomic, and geographic patient disparities in such studies, which threaten to bias findings and eventually care towards select patient populations [11][12][13][14] . Commercial sequencing options for prostate cancer are emerging, but such approaches are often proprietary, only available to patients with appropriate insurance, and regularly inaccessible for wider research use [15][16][17] .…”

Section: Introductionmentioning

confidence: 99%

A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project

Crowdis

Balch

Sterlin

et al. 2021

Preprint

View full text Add to dashboard Cite

Molecular profiling studies have enabled numerous discoveries for metastatic prostate cancer (MPC), but they have mostly occurred in academic medical institutions focused on select patient populations. We developed the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to empower MPC patients living anywhere in the U.S. and Canada to participate in molecular research and contribute directly to translational discovery. Here we present clinicogenomic results from our partnership with the first 706 MPCproject participants. We found that a patient-centered and remote research strategy enhanced engagement with patients in rural and medically underserved areas. Furthermore, patient-reported data achieved 90% consistency with abstracted health records for therapies and provided a mechanism for patient-partners to share information about their cancer experience not documented in medical records. Among the molecular profiling data from 333 patient-partners (n = 573 samples), whole exome sequencing of 63 tumor samples obtained from hospitals across the U.S. and Canada and 19 plasma cell-free DNA (cfDNA) samples from blood donated remotely recapitulated known findings in MPC and enabled longitudinal study of prostate cancer evolution. Inexpensive ultra-low coverage whole genome sequencing of 318 cfDNA samples from donated blood revealed clinically relevant genomic changes like AR amplification, even in the context of low tumor burden. Collectively, this study illustrates the power of a longitudinal partnership with patients to generate a more representative clinical and molecular understanding of MPC. Note: To assist our patient-partners and the wider MPC community interpret the results of this study, we have attached a supplemental glossary of terms.

show abstract

Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation

Cited by 16 publications

References 33 publications

Mentoring Programs by and for a New Generation of Latino Investigators in Behavioral-Social Science HIV Research

Mentoring Programs by and for a New Generation of Latino Investigators in Behavioral-Social Science HIV Research

Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology

A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project

Contact Info

Product

Resources

About